- Home
- SPPL vs SNGX Comparison
SPPL vs SNGX Comparison
Compare SPPL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- SNGX
- Stock Information
- Founded
- SPPL 2016
- SNGX 1987
- Country
- SPPL Singapore
- SNGX United States
- Employees
- SPPL N/A
- SNGX N/A
- Industry
- SPPL
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- SNGX Health Care
- Exchange
- SPPL Nasdaq
- SNGX Nasdaq
- Market Cap
- SPPL 9.8M
- SNGX 10.1M
- IPO Year
- SPPL 2023
- SNGX 1987
- Fundamental
- Price
- SPPL $4.45
- SNGX $2.82
- Analyst Decision
- SPPL
- SNGX Strong Buy
- Analyst Count
- SPPL 0
- SNGX 1
- Target Price
- SPPL N/A
- SNGX $6.00
- AVG Volume (30 Days)
- SPPL 24.4K
- SNGX 10.0M
- Earning Date
- SPPL 01-01-0001
- SNGX 11-07-2025
- Dividend Yield
- SPPL N/A
- SNGX N/A
- EPS Growth
- SPPL N/A
- SNGX N/A
- EPS
- SPPL N/A
- SNGX N/A
- Revenue
- SPPL $2,764,846.00
- SNGX N/A
- Revenue This Year
- SPPL N/A
- SNGX N/A
- Revenue Next Year
- SPPL N/A
- SNGX N/A
- P/E Ratio
- SPPL N/A
- SNGX N/A
- Revenue Growth
- SPPL N/A
- SNGX N/A
- 52 Week Low
- SPPL $2.16
- SNGX $1.09
- 52 Week High
- SPPL $16.80
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- SPPL 71.63
- SNGX 49.67
- Support Level
- SPPL $3.00
- SNGX $2.58
- Resistance Level
- SPPL $4.79
- SNGX $2.98
- Average True Range (ATR)
- SPPL 0.24
- SNGX 0.19
- MACD
- SPPL 0.16
- SNGX -0.07
- Stochastic Oscillator
- SPPL 81.52
- SNGX 37.50
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).